Screening Checklist for Contraindications to Injectable Influenza Vaccine (Inactivated "IIV," Cell Culture "ccIIV," Recombinant "RIV," or mRNA)

PATIENT NAME _____

DATE OF BIRTH ____/____/____
month day year

For patients (both children and adults) to be vaccinated: The following questions will help us determine if there is any reason we should not give you or your child injectable influenza vaccination today. If you answer "yes" to any question, it does not necessarily mean you (or your child) should not be vaccinated. It just means additional questions must be asked. If a question is not clear, please ask your healthcare provider to explain it.

	yes	no	don't know
1. Is the person to be vaccinated sick today?	☐	☐	☐
2. Does the person to be vaccinated have an allergy to an ingredient of the vaccine?	☐	☐	☐
3. Has the person to be vaccinated ever had a serious reaction to influenza vaccine in the past?	☐	☐	☐
4. Has the person to be vaccinated ever had Guillain Barré Syndrome?	☐	☐	☐
5. Has the person to be vaccinated ever felt dizzy or faint before, during, or after a shot?	☐	☐	☐
6. Is the person to be vaccinated anxious about getting a shot today?	☐	☐	☐

FORM COMPLETED BY _____ DATE _____

FORM REVIEWED BY _____ DATE _____

Information for Healthcare Professionals about the Screening Checklist for Contraindications to Injectable Influenza Vaccine (Inactivated "IIV," Cell Culture "ccIIV," Recombinant "RIV," or mRNA)

For additional details, see resources listed below.

For supporting documentation on the answers given below, refer to CDC's Interim Clinical Considerations for the Use of Seasonal Influenza Vaccines in the United States (www.cdc.gov/flu/hcp/vax-summary/seasonal-influenza-vaccines.html) and to the product package inserts.

1. **Is the person to be vaccinated sick today?**

   There is no evidence that acute illness reduces vaccine efficacy or increases vaccine adverse events. People with a moderate or severe illness usually should not be vaccinated until their symptoms have improved. Minor illnesses with or without fever do not contraindicate use of influenza vaccine. Do not withhold vaccination if a person is taking antibiotics.

2. **Does the person to be vaccinated have an allergy to an ingredient of the vaccine?**

   All vaccines, including influenza vaccines, contain various components that might cause allergic reactions, including anaphylaxis.

   CDC does not consider egg allergy of any severity to be a contraindication or precaution to egg-based influenza vaccines: people with any type of egg allergy may receive any influenza vaccine (egg-based or non-egg-based) that is otherwise appropriate for their age and health status.

   IIV provided in multidose vials contains thimerosal as a preservative. Most people who had sensitivity to thimerosal when it was used in contact lens solution do not have reactions to thimerosal when it is used in vaccines.

   The mRNA influenza vaccine contains polyethylene glycol, but does not contain gelatin, egg protein, or antibiotics.

   Check the package insert of a specific influenza vaccine at www.immunize.org/official-guidance/fda/pkg-inserts for a list of the vaccine components (i.e., excipients and culture media) used in the production of the vaccine, or go to www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states.

   For the 2026–2027 influenza season, no vaccine or packaging contains latex.

3. **Has the person to be vaccinated ever had a serious reaction to influenza vaccine in the past?**

   Patients reporting a serious reaction to a previous dose of influenza vaccine should be asked to describe their symptoms. Immediate—presumably allergic—reactions are usually a contraindication or a precaution to influenza vaccination, depending upon the type of vaccine that triggered the reaction and the types of vaccine available for use. Do not give any egg-based IIV to a person who has experienced a serious systemic or anaphylactic reaction to a prior dose of an influenza vaccine (i.e., egg-based IIV, ccIIV, RIV, or live attenuated influenza vaccine [LAIV]). For ccIIV, history of a severe allergic reaction (e.g., anaphylaxis) to any ccIIV or any component of ccIIV is a contraindication to future use of ccIIV. For RIV, history of a severe allergic reaction (e.g., anaphylaxis) to any RIV or any component of RIV is a contraindication to future use of RIV.

   Fever, malaise, myalgia, and other systemic symptoms most often affect people who are first-time vaccinees. These reactions are not a contraindication to future vaccination. These people can receive injectable vaccine without further evaluation.

   A history of a severe allergic reaction to a previous dose of any egg-based IIV, LAIV, or RIV is a precaution to use of ccIIV. A history of a severe allergic reaction to a previous dose of any egg-based IIV, ccIIV, or LAIV is a precaution to use of RIV. Use of ccIIV and RIV in such instances should occur in an inpatient or outpatient medical setting under supervision of a provider who can recognize and manage a severe allergic reaction; providers should consider consulting with an allergist to help identify the vaccine component responsible for the reaction.

   The mRNA influenza vaccine, first FDA-licensed in August 2026, should not be used if a person has had a serious allergic reaction to any vaccine component. The package insert does not indicate any precaution or contraindication to use of the mRNA influenza vaccine after a serious allergic reaction to any non-mRNA influenza vaccine.

4. **Has the person to be vaccinated ever had Guillain-Barré Syndrome?**

   People who are not at high risk for severe influenza complications and who are known to have developed Guillain-Barré syndrome (GBS) within 6 weeks after receiving a previous influenza vaccination should not be vaccinated. As an alternative, clinicians might consider using influenza antiviral chemoprophylaxis for these people. However, the benefits of influenza vaccination might outweigh the possible risks for certain people who have a history of GBS within 6 weeks after receipt of influenza vaccine and who are at higher risk for severe complications from influenza.

5. **Has the person to be vaccinated ever felt dizzy or faint before, during, or after a shot?**

   Fainting (syncope) or dizziness (presyncope) is not a contraindication or precaution to vaccination. However, for some people these can be a response to vaccination anxiety. People in adolescent and young adult age groups are more likely to experience syncope. CDC recommends that vaccine providers consider observing all patients for 15 minutes after vaccination with the person seated or lying down. This is especially important for people with a pattern of injection-related syncope. For more information about vaccination-related syncope, see www.immunize.org/catg.d/p4260.pdf.

6. **Is the person to be vaccinated anxious about getting a shot today?**

   Anxiety can lead to vaccine hesitancy or avoidance. Simple steps can help reduce a patient's anxiety about vaccination. Visit Immunize.org's "Improving the Vaccination Experience" for clinical resources by going to www.immunize.org/clinical/vaccine-confidence/topic/improving-vaccine-experience/.